# Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

> **NCT06577519** · PHASE3 · RECRUITING · sponsor: **Jiangsu vcare pharmaceutical technology co., LTD** · enrollment: 1000 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

## Interventions

- **DRUG:** Vicagrel
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT06577519
- **Lead sponsor:** Jiangsu vcare pharmaceutical technology co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-06
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577519, "Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06577519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*